Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.280
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.300
+0.020 (1.56%)
After-hours: Apr 28, 2026, 7:58 PM EDT
Cognition Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Selling, General & Admin | 10.61 | 12.29 | 13.53 | 13.23 | 10.03 | |
| Research & Development | 37.19 | 41.68 | 37.2 | 30.32 | 18.57 | |
| Operating Expenses | 47.8 | 53.97 | 50.72 | 43.55 | 28.6 | |
| Operating Income | -47.8 | -53.97 | -50.72 | -43.55 | -28.6 | |
| Interest Expense | -0.01 | -0.03 | -0.03 | -0.03 | -0.89 | |
| Currency Exchange Gain (Loss) | - | -0.2 | - | - | - | |
| Other Non Operating Income (Expenses) | 24.33 | 20.22 | 24.96 | 22.18 | 17.33 | |
| EBT Excluding Unusual Items | -23.49 | -33.97 | -25.79 | -21.4 | -12.16 | |
| Other Unusual Items | - | - | - | - | 0.44 | |
| Pretax Income | -23.49 | -33.97 | -25.79 | -21.4 | -11.72 | |
| Net Income | -23.49 | -33.97 | -25.79 | -21.4 | -11.72 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 4.53 | |
| Net Income to Common | -23.49 | -33.97 | -25.79 | -21.4 | -16.25 | |
| Shares Outstanding (Basic) | 73 | 40 | 30 | 24 | 5 | |
| Shares Outstanding (Diluted) | 73 | 40 | 30 | 24 | 5 | |
| Shares Change (YoY) | 83.15% | 32.31% | 27.03% | 355.42% | 921.60% | |
| EPS (Basic) | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 | |
| EPS (Diluted) | -0.32 | -0.86 | -0.86 | -0.91 | -3.13 | |
| Free Cash Flow | -24.59 | -28.48 | -16.17 | -18.7 | -3.66 | |
| Free Cash Flow Per Share | -0.34 | -0.72 | -0.54 | -0.79 | -0.70 | |
| EBITDA | -47.76 | -53.86 | -50.63 | -43.47 | -28.51 | |
| D&A For EBITDA | 0.04 | 0.11 | 0.1 | 0.08 | 0.09 | |
| EBIT | -47.8 | -53.97 | -50.72 | -43.55 | -28.6 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.